Profile
Russell H.
Plumb served as President, CEO, CFO, Secretary & Treasurer at Inhibitex LLC from 2010 to 2012.
Prior to that, he was the Chief Financial Officer & Vice President at Serologicals Corp.
from 1994 to 1999 and the Chief Financial Officer at Emory Vision from 1999 to 2000.
He also served as Executive Chairman & Chief Financial Officer at Aviragen Therapeutics, Inc. in 2015 and as a Director at AerovectRx Corp.
He obtained his undergraduate degree and MBA from the University of Toronto.
Former positions of Russell H. Plumb
| Companies | Position | End |
|---|---|---|
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | President | 2012-02-12 |
| Emory Vision | Director of Finance/CFO | 2000-06-30 |
Serologicals Corp.
 Serologicals Corp. Miscellaneous Commercial ServicesCommercial Services Serologicals Corp. researches, develops and markets biological products for the life sciences market. The firm focuses in areas such as are cell culture supplements, molecular reagents and diagnostic antibodies. Its applications include cardiology, hematology, infectious diseases, immunology, molecular biology and oncology. It has operations in Australia, Canada, Scotland, and United Kingdom. The company was founded in 1971 by Samuel A. Penninger and is located in Norcross, GA. | Director of Finance/CFO | 1999-10-31 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Chief Executive Officer | 2014-09-30 |
AerovectRx Corp.
 AerovectRx Corp. Pharmaceuticals: MajorHealth Technology AerovectRx Corp. provides dosage controlled solutions to the inhaled drug delivery market. It offers AeroCell disposable drug cartridge for inhaled delivery of drugs, vaccines, and therapeutics. AerovectRx technology includes treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management and for delivery of vaccines and anti-viral drugs. The company was founded in 2005 and is headquartered in Atlanta, GA. | Director/Board Member | - |
Training of Russell H. Plumb
| University of Toronto | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Serologicals Corp.
Serologicals Corp. Miscellaneous Commercial ServicesCommercial Services Serologicals Corp. researches, develops and markets biological products for the life sciences market. The firm focuses in areas such as are cell culture supplements, molecular reagents and diagnostic antibodies. Its applications include cardiology, hematology, infectious diseases, immunology, molecular biology and oncology. It has operations in Australia, Canada, Scotland, and United Kingdom. The company was founded in 1971 by Samuel A. Penninger and is located in Norcross, GA. | Commercial Services |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
AerovectRx Corp.
AerovectRx Corp. Pharmaceuticals: MajorHealth Technology AerovectRx Corp. provides dosage controlled solutions to the inhaled drug delivery market. It offers AeroCell disposable drug cartridge for inhaled delivery of drugs, vaccines, and therapeutics. AerovectRx technology includes treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management and for delivery of vaccines and anti-viral drugs. The company was founded in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Emory Vision | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Stock Market
- Insiders
- Russell H. Plumb
